Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono’s Erbitux to receive CDF funding in England

Merck Serono’s Erbitux to receive CDF funding in England

7th March 2014

Merck Serono has announced that England's Cancer Drugs Fund (CDF) has agreed to provide financial support to help colorectal cancer patients gain access to its drug Erbitux.

The therapy is specified for first-line use in combination with oxaliplatin-based chemotherapy FOLFOX4, FOLFOX6 or OxMdG, for patients with EGFR-expressing, RAS wild-type metastatic colorectal cancer.

Erbitux will now be funded in combination with oxaliplatin by the CDF in addition to its use in combination with irinotecan-based chemotherapy, or as a single agent in patients who have failed oxaliplatin and irinotecan-based therapy, and are intolerant to irinotecan.

The decision was based on positive safety and efficacy results from the Opus trial, which showed the progression-free survival benefits associated with the drug.

David Garmon-Jones, general manager for Merck Serono in the UK and Ireland, said: "This is potentially good news for the patients with RAS wild-type metastatic colorectal cancer in England, as it will mean that there is yet another treatment option open to them."

The product was approved in Europe for use in the treatment of patients with RAS wild-type metastatic colorectal cancer at the end of last year.ADNFCR-8000103-ID-801701304-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.